APLM Apollomics Inc.

Nasdaq N/A


$ 28.21 $ -0.97 (-3.33 %)    

Thursday, 23-Oct-2025 15:55:19 EDT
QQQ $ 613.12 $ 0.00 (0 %)
DIA $ 467.31 $ 0.00 (0 %)
SPY $ 673.29 $ 0.00 (0 %)
TLT $ 91.34 $ 0.00 (0 %)
GLD $ 372.83 $ 0.00 (0 %)
$ 28.2131
$ 29.87
$ 26.62 x 30
$ 38.00 x 60
-- - --
$ 3.66 - $ 42.12
16,681
na
31.13M
$ 0.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 apollomics-receives-39m-payment-from-launxp-maintains-active-collaboration-on-vebreltinib-development

Pursuant to the Company's Form 6-K filed on July 25, 2025 (the "July 2025 6-K"), Apollomics Inc. ("Apollomics&#...

 nasdaq-cancels-delisting-hearing-for-apollomics-confirms-compliance-with-continued-listing-standards

Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharma...

Core News & Articles

The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:AP...

 apollomics-fy24-eps-5280-up-from-23199-yoy

Apollomics (NASDAQ:APLM) reported quarterly losses of $(52.80) per share. This is a 77.24 percent increase over losses of $(231...

 apollomics-and-launxp-announce-development-and-commercialization-agreement-for-vebreltinib-apollomics-to-receive-upfront-payments-of-10m-and-is-eligible-for-pre-commercial-milestones-up-to-50m-and-royalties-on-net-product-sales

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asi...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION